UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.   | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|---------------------|------------------|
| 10/590,326  | 08/23/2006  | Jordi Tormo i Blasco | 5000-0193PUS1       | 8108             |
| 2292 7590 11/13/2009 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040 0747 |             |                      | EXAMINER            |                  |
|   |             |                      | MURRAY, JEFFREY H   |                  |
| FALLS CHURCH, VA 22040-0747   |             |                      | ART UNIT            | PAPER NUMBER     |
|   |             |                      | 1624                |                  |
|   |             |                      |                     |                  |
|   |             |                      | NOTIFICATION DATE   | DELIVERY MODE    |
|   |             |                      | 11/13/2009          | ELECTRONIC       |

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

|   | Application No.   | Applicant(s)  |  |  |  |
|---|---|---|--|--|--|
|   | 10/590,326  | I BLASCO ET AL.   |  |  |  |
| Office Action Summary   | Examiner  | Art Unit  |  |  |  |
|   | JEFFREY H. MURRAY   | 1624  |  |  |  |
| The MAILING DATE of this communication app<br>Period for Reply  | ears on the cover sheet with the c  | orrespondence address   |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w.  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).   | ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE | lely filed the mailing date of this communication. (35 U.S.C. § 133). |  |  |  |
| Status  |   |   |  |  |  |
| Responsive to communication(s) filed on <u>22 Jules</u> This action is <b>FINAL</b> . 2b) ☑ This     Since this application is in condition for alloware closed in accordance with the practice under E   | action is non-final.<br>nce except for formal matters, pro  |   |  |  |  |
| Disposition of Claims   |   |   |  |  |  |
| 4) ☐ Claim(s) 1-16 is/are pending in the application. 4a) Of the above claim(s) 10-13,15 and 16 is/ar 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-9 and 14 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examine 10) ☐ The drawing(s) filed on is/are: a) ☐ access   | e withdrawn from consideration.  election requirement.  | Examiner.   |  |  |  |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.   |   |   |  |  |  |
| Priority under 35 U.S.C. § 119  |   |   |  |  |  |
| <ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul> |   |   |  |  |  |
| Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 8/23/2006.   | 4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:  | ite   |  |  |  |

Art Unit: 1624

## **DETAILED ACTION**

This action is in response to an election from a restriction requirement filed on July 22, 2009. There are sixteen claims pending and ten claims under consideration. Claims 11-13, 15 and 16 have been withdrawn. This is the first action on the merits. The present invention relates to 5,6-dialkyl-7-aminotriazolopyrimidines, methods of making and methods of using.

Election was made **with** traverse in the reply filed on July 22, 2009. Applicants have pointed out that while the CAS search showed a 7-aminotriazolopyrimidine compound in Heimbach, et. al., U.S. Patent No. 2,444,605, the compound does not in fact exist in this document. While applicants are correct in their assessment, there are other prior art documents which do contain such compounds. For example, Levin, et. al., Zhurnal Obshchei Khimii (1963), 33(8), 2678-82 contains a 5-ethyl-6-methyl-7-aminotriazolopyrimidine compound (p. 2679, 4<sup>th</sup> example in table) which breaks the unity of invention as there is no special technical feature seen with respect to the R<sup>1</sup> and R<sup>2</sup> groups. Therefore this restriction is considered proper and thus made **FINAL**.

## Specification

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

## **Arrangement of the Specification**

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.

Art Unit: 1624

(c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.

- (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT.
- (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC.
- (f) BACKGROUND OF THE INVENTION.
  - (1) Field of the Invention.
  - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (g) BRIEF SUMMARY OF THE INVENTION.
- (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (i) DETAILED DESCRIPTION OF THE INVENTION.
- (j) CLAIM OR CLAIMS (commencing on a separate sheet).
- (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (I) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any of the errors of which applicant may become aware of in the specification.

#### Claim Objections

Claim 1 is objected to because of the following informalities: Claim 1 reads, "The triazolopyrimidine of the formula...". This is improper. The claim should read, "The compound of formula...". Appropriate correction is required.

# Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory

obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-9 and 14 are provisionally rejected on the ground of nonstatutory anticipatory-type double patenting as being unpatentable over claim 1 of U.S. Patent Application Nos. 10/484,250; 10/590,368; 10/589,876; and 10/589,953. Although the conflicting claims are not identical, they are not patentably distinct from each other

Art Unit: 1624

because Claim 1 of U.S. Patent Application Nos. 10/484,250; 10/590,368; 10/589,876; and 10/589,953 embrace the instant claims 1-9 and 14.

Claim 1 of the current application teaches the following structure:

Where R¹ and R² can both be alkyl groups or R¹ can be al alkoxy group. All of the copending applications teach some narrowed species of this compound, whereby the alkyl group or alkoxy group is narrowed in scope. The instant claim differs from the copending claim by a more limited genus than the claim of the copending application. However, it would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus of the copending application, including those instantly claimed, because the skilled chemist would have the reasonable expectation that any of the species of the genus would have similar properties and, thus, the same use as taught for the genus as a whole. One of ordinary skill in the art would have been motivated to select the claimed compounds from the genus of the copending application since such compounds would have been suggested by the claims of the copending application. It has been held that a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. *In re Susi*, 440 F.2d 442, 169 USPQ 423, 425 (CCPA 1971), followed

Art Unit: 1624

by the Federal Circuit in *Merck & Co. v. Biocraft Laboratories*, 847 F.2d 804, 10 USPQ 2d 1843, 1846 (Fed. Cir. 1989).

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant is advised that should claim 1 be found allowable, claim 3, which is a multiple dependent claim will be objected to under 37 CFR 1.75 as being in part, a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k). Since claim 3 is dependent on both claims 1 and 2, it is recommended that the applicants remove the claim 1 dependency from claim 3. No new matter permitted. Appropriate correction is required.

#### Conclusion

Claim 1-9 and 14 are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey H. Murray whose telephone number is 571-272-9023. The examiner can normally be reached on Mon.-Thurs. 7:30-6pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisors, Mr. James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jeffrey H Murray/ Patent Examiner , Art Unit 1624 /James O. Wilson/ Supervisory Patent Examiner, Art Unit 1624